1. Home
  2. SION vs NVTS Comparison

SION vs NVTS Comparison

Compare SION & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SION
  • NVTS
  • Stock Information
  • Founded
  • SION 2019
  • NVTS 2014
  • Country
  • SION United States
  • NVTS United States
  • Employees
  • SION N/A
  • NVTS N/A
  • Industry
  • SION
  • NVTS Semiconductors
  • Sector
  • SION
  • NVTS Technology
  • Exchange
  • SION NYSE
  • NVTS Nasdaq
  • Market Cap
  • SION 338.0M
  • NVTS 383.0M
  • IPO Year
  • SION 2025
  • NVTS N/A
  • Fundamental
  • Price
  • SION $12.57
  • NVTS $1.90
  • Analyst Decision
  • SION Strong Buy
  • NVTS Buy
  • Analyst Count
  • SION 1
  • NVTS 7
  • Target Price
  • SION $32.00
  • NVTS $3.54
  • AVG Volume (30 Days)
  • SION 128.6K
  • NVTS 2.7M
  • Earning Date
  • SION 05-25-2025
  • NVTS 05-05-2025
  • Dividend Yield
  • SION N/A
  • NVTS N/A
  • EPS Growth
  • SION N/A
  • NVTS N/A
  • EPS
  • SION N/A
  • NVTS N/A
  • Revenue
  • SION N/A
  • NVTS $74,145,000.00
  • Revenue This Year
  • SION N/A
  • NVTS N/A
  • Revenue Next Year
  • SION N/A
  • NVTS $46.80
  • P/E Ratio
  • SION N/A
  • NVTS N/A
  • Revenue Growth
  • SION N/A
  • NVTS N/A
  • 52 Week Low
  • SION $7.26
  • NVTS $1.52
  • 52 Week High
  • SION $25.19
  • NVTS $5.14
  • Technical
  • Relative Strength Index (RSI)
  • SION N/A
  • NVTS 46.52
  • Support Level
  • SION N/A
  • NVTS $1.80
  • Resistance Level
  • SION N/A
  • NVTS $2.10
  • Average True Range (ATR)
  • SION 0.00
  • NVTS 0.11
  • MACD
  • SION 0.00
  • NVTS 0.02
  • Stochastic Oscillator
  • SION 0.00
  • NVTS 45.21

About SION SIONNA THERAPEUTICS INC

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.

Share on Social Networks: